
Yair Y Reisner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4002034/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	OUP accepted manuscript. Stem Cells Translational Medicine, 2022, 11, 178-188.	1.6	Ο
2	Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cells. Bone Marrow Transplantation, 2021, 56, 1818-1827.	1.3	2
3	The use of pre-conditioning and novel assays in the development of protocols for transplantation of lung progenitors. , 2021, , 232-247.		1
4	Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors. , 2021, 9, e003404.		11
5	Multi-lineage Lung Regeneration by Stem Cell Transplantation across Major Genetic Barriers. Cell Reports, 2020, 30, 807-819.e4.	2.9	20
6	Toward safer haploidnetical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2019, 54, 733-737.	1.3	3
7	Haploidentical HSCT–going from strength to strength. Bone Marrow Transplantation, 2019, 54, 687-688.	1.3	1
8	Veto cells for safer nonmyeloablative haploidentical HSCT and CAR T cell therapy. Seminars in Hematology, 2019, 56, 173-182.	1.8	5
9	Next-generation CD8 memory veto T cells directed against memory antigens. Leukemia, 2019, 33, 2737-2741.	3.3	4
10	Lung Injury Repair by Transplantation of Adult Lung Cells Following Preconditioning of Recipient Mice. Stem Cells Translational Medicine, 2018, 7, 68-77.	1.6	15
11	Historical Perspective and Current Trends in Haploidentical Transplantation. , 2018, , 1-11.		0
12	Toward Safer CD34+ Megadose T-Cell-Depleted Transplants Following Reduced Intensity and Nonmyeloablative Conditioning Regimens. , 2018, , 15-28.		0
13	Novel immunoregulatory role of perforin-positive dendritic cells. Seminars in Immunopathology, 2017, 39, 121-133.	2.8	7
14	Immune tolerance induction by nonmyeloablative haploidentical HSCT combining T-cell depletion and posttransplant cyclophosphamide. Blood Advances, 2017, 1, 2166-2175.	2.5	16
15	Haploidentical Family Donor Transplantation: At the Crossroads of a Changing Paradigm. Advances in Hematology, 2016, 2016, 1-2.	0.6	0
16	The evolution of Tâ€cell depletion in haploidentical stemâ€cell transplantation. British Journal of Haematology, 2016, 172, 667-684.	1.2	49
17	Assessing remyelination - metabolic labeling of myelin in an animal model of multiple sclerosis. Journal of Neuroimmunology, 2016, 301, 7-11.	1.1	10
18	Next Generation Veto Cells for Non-Myeloablative Haploidentical HSCT: Combining Anti-Viral and Graft Facilitating Activity. Blood, 2016, 128, 3345-3345.	0.6	3

#	Article	IF	CITATIONS
19	Towards 'Off-the-Shelf ' Universal Chimeric Antigen Receptor (CAR) T Cells: Mouse Anti-3rd Party Central Memory CD8 Veto Cells Prolong Functional Engraftment of Allogeneic Genetically Modified T Cells. Blood, 2016, 128, 2171-2171.	0.6	0
20	High Levels of Hematopoietic Progenitors in the Fetal Lung Enable Induction of Immune Tolerance and Co-Transplantation of Epithelial Progenitors for Repair of Lung Injury Across MHC Barriers. Blood, 2016, 128, 1477-1477.	0.6	0
21	Transplantation of T Cell Depleted Haploidentical HSCT Following Non-Myeloablative (NMA) Conditioning: Combining the Power of Megadose Transplants with Post Transplant Cyclophosphamide (PTCY). Blood, 2016, 128, 5765-5765.	0.6	0
22	Thrombin induces ischemic LTP (iLTP): implications for synaptic plasticity in the acute phase of ischemic stroke. Scientific Reports, 2015, 5, 7912.	1.6	57
23	Exercising â€~veto' power to make haploidentical hematopoietic stem cell transplantation a safe modality for induction of immune tolerance. Regenerative Medicine, 2015, 10, 239-242.	0.8	4
24	Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice. Nature Medicine, 2015, 21, 869-879.	15.2	93
25	Perforin-Positive Dendritic Cells Exhibit an Immuno-regulatory Role in Metabolic Syndrome and Autoimmunity. Immunity, 2015, 43, 776-787.	6.6	55
26	Megadose stem cell administration as a route to mixed chimerism. Current Opinion in Organ Transplantation, 2014, 19, 334-341.	0.8	10
27	"Designed―grafts for HLA-haploidentical stem cell transplantation. Blood, 2014, 123, 967-973.	0.6	71
28	HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood, 2014, 124, 638-644.	0.6	358
29	A novel role for factor VIII and thrombin/PAR1 in regulating hematopoiesis and its interplay with the bone structure. Blood, 2013, 122, 2562-2571.	0.6	38
30	Fetal Pancreas as a Source for Islet Transplantation. Diabetes, 2013, 62, 1382-1383.	0.3	2
31	A new approach for eradication of residual lymphoma cells by host nonreactive anti–third-party central memory CD8 T cells. Blood, 2013, 121, 3033-3040.	0.6	3
32	Murine anti–third-party central-memory CD8+ T cells promote hematopoietic chimerism under mild conditioning: lymph-node sequestration and deletion of anti-donor T cells. Blood, 2013, 121, 1220-1228.	0.6	24
33	Growing Organs for Transplantation from Embryonic Precursor Tissues. , 2013, , 365-375.		0
34	The use of donor-derived veto cells in hematopoietic stem cell transplantation. Frontiers in Immunology, 2012, 3, 93.	2.2	9
35	Deletion of cognate CD8 T cells by immature dendritic cells: a novel role for perforin, granzyme A, TREM-1, and TLR7. Blood, 2012, 120, 1647-1657.	0.6	33
36	Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: Risk stratified approach with a longâ€ŧerm followâ€up. American Journal of Hematology, 2012, 87, 875-879.	2.0	6

#	Article	IF	CITATIONS
37	Nathan Sharon. Advances in Carbohydrate Chemistry and Biochemistry, 2012, 67, 2-18.	0.4	Ο
38	Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood, 2011, 117, 3921-3928.	0.6	940
39	Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency: Stem Cell Selection and Manipulation. Hematology/Oncology Clinics of North America, 2011, 25, 45-62.	0.9	4
40	Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. Best Practice and Research in Clinical Haematology, 2011, 24, 459-466.	0.7	40
41	Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: The role of ex-vivo generated donor CD8+ T cells with central memory phenotype. Best Practice and Research in Clinical Haematology, 2011, 24, 393-401.	0.7	2
42	Preface. Best Practice and Research in Clinical Haematology, 2011, 24, 323-324.	0.7	1
43	CTLs respond with activation and granule secretion when serving as targets for T-cell recognition. Blood, 2011, 117, 1042-1052.	0.6	41
44	Haploidentical hematopoietic transplantation: current status and future perspectives. Blood, 2011, 118, 6006-6017.	0.6	155
45	TCR-Independent Killing of B Cell Malignancies by Anti–Third-Party CTLs: The Critical Role of MHC–CD8 Engagement. Journal of Immunology, 2011, 187, 2006-2014.	0.4	5
46	Embryonic Pig Pancreatic Tissue for the Treatment of Diabetes: Potential Role of Immune Suppression With "Off-the-Shelf―Third-Party Regulatory T Cells. Transplantation, 2011, 91, 398-405.	0.5	8
47	Growth Enhancement by Embryonic Fibroblasts Upon Cotransplantation of Noncommitted Pig Embryonic Tissues With Fully Committed Organs. Transplantation, 2010, 89, 1198-1207.	0.5	1
48	Deletion of Alloreactive T Cells by Veto Cytotoxic T Lymphocytes Is Mediated Through Extracellular Signal-Regulated Kinase Phosphorylation. Transplantation, 2010, 90, 380-386.	0.5	9
49	Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency: Stem Cell Selection and Manipulation. Immunology and Allergy Clinics of North America, 2010, 30, 45-62.	0.7	7
50	Induction of tolerance to bone marrow allografts by donor-derived host nonreactive ex vivo–induced central memory CD8 T cells. Blood, 2010, 115, 2095-2104.	0.6	24
51	Ex Vivo Generated Donor Central Memory CD8 T Cells, Previously Shown to Enhance Engraftment of Allogeneic Bone Marrow, Also Exhibit Significant GVL Activity without Causing Gvhd In An In Vivo b Cell Lymphoma Model. Blood, 2010, 116, 424-424.	0.6	4
52	Embryonic Porcine Skin Precursors Can Successfully Develop into Integrated Skin without Teratoma Formation Posttransplantation in Nude Mouse Model. PLoS ONE, 2010, 5, e8717.	1.1	8
53	Crossing HLA Barriers by "Megadose―Stem Cell Transplants. , 2010, , 1-27.		0
54	The Hanleidantical Ontion for High Dich Hamatelegical Malignanciae 2010 20.52		0

54 The Haploidentical Option for High-Risk Hematological Malignancies. , 2010, , 29-52.

0

#	Article	IF	CITATIONS
55	Bone Marrow Transplantation Across Major Genetic Barriers. , 2010, , .		ο
56	Pig Embryonic Pancreatic Tissue as a Source for Transplantation in Diabetes. Diabetes, 2009, 58, 1585-1594.	0.3	33
57	Embryonic pig pancreatic tissue for the treatment of diabetes in a nonhuman primate model. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8659-8664.	3.3	89
58	Direct Imaging of Immune Rejection and Memory Induction by Allogeneic Mesenchymal Stromal Cells. Stem Cells, 2009, 27, 2865-2874.	1.4	230
59	Induction of tolerance in organ recipients by hematopoietic stem cell transplantation. International Immunopharmacology, 2009, 9, 694-700.	1.7	8
60	Adoptive Immunotherapy with Tregs Prevents GvHD and Favours Immune Reconstitution After HLA Haploidentical Transplants for Hematological Malignancies Blood, 2009, 114, 4-4.	0.6	14
61	Tolerance Induction by Immature Dendritic Cells Is Mediated by Distinct MHC Dependent and Independent Mechanisms: A Novel Role for Perforin, Granzyme A and Toll Like Receptor 7 Blood, 2009, 114, 65-65.	0.6	4
62	Enhancement of Pig Embryonic Implants in Factor VIII KO Mice: A Novel Role for the Coagulation Cascade in Organ Size Control. PLoS ONE, 2009, 4, e8362.	1.1	1
63	Embryonic Porcine Liver as a Source for Transplantation: Advantage of Intact Liver Implants over Isolated Hepatoblasts in Overcoming Homeostatic Inhibition by the Quiescent Host Liver. Stem Cells, 2008, 26, 1347-1355.	1.4	14
64	From â€~megadose' haploidentical hematopoietic stem cell transplants in acute leukemia to tolerance induction in organ transplantation. Blood Cells, Molecules, and Diseases, 2008, 40, 1-7.	0.6	15
65	The haploidentical option for high-risk haematological malignancies. Blood Cells, Molecules, and Diseases, 2008, 40, 8-12.	0.6	53
66	Large-scale generation of human allodepleted anti-3rd party lymphocytes. Blood Cells, Molecules, and Diseases, 2008, 40, 106-112.	0.6	0
67	Nanoscale Increases in CD2-CD48-mediated Intermembrane Spacing Decrease Adhesion and Reorganize the Immunological Synapse. Journal of Biological Chemistry, 2008, 283, 34414-34422.	1.6	66
68	Estimating Cell Depth from Somatic Mutations. PLoS Computational Biology, 2008, 4, e1000058.	1.5	35
69	Reconstruction of Cell Lineage Trees in Mice. PLoS ONE, 2008, 3, e1939.	1.1	43
70	Tolerance Induction in Presensitized Bone Marrow Recipients by Veto CTLs: Effective Deletion of Host Anti-Donor Memory Effector Cells. Journal of Immunology, 2007, 179, 6389-6394.	0.4	16
71	Safe and Efficacious Allogeneic Bone Marrow Transplantation for Nonmalignant Disorders Using Partial T Cell Depletion and No Posttransplantation Graft-Versus-Host-Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2007, 13, 329-338.	2.0	12
72	Hematopoietic stem cell transplantation across major genetic barriers. Immunologic Research, 2007, 38, 174-190.	1.3	3

#	Article	IF	CITATIONS
73	Growing organs for transplantation from embryonic precursor tissues. Immunologic Research, 2007, 38, 261-273.	1.3	5
74	Eradication of B Cell Malignancies by Anti-3rd Party CTLs: A Novel Role for MHC Class I Blood, 2007, 110, 2759-2759.	0.6	2
75	Hematopoietic stem cell transplantation across major genetic barriers. Immunologic Research, 2007, 38, 174-90.	1.3	0
76	Embryonic Pig Pancreatic Tissue Transplantation for the Treatment of Diabetes. PLoS Medicine, 2006, 3, e215.	3.9	59
77	The role of veto cells in bone marrow transplantation. Current Opinion in Organ Transplantation, 2006, 11, 366-372.	0.8	7
78	Human Embryonic Stem Cells and Their Differentiated Derivatives Are Less Susceptible to Immune Rejection Than Adult Cells. Stem Cells, 2006, 24, 221-229.	1.4	378
79	Transplantation of Human Hematopoietic Stem Cells into Ischemic and Growing Kidneys Suggests a Role in Vasculogenesis but Not Tubulogenesis. Stem Cells, 2006, 24, 1185-1193.	1.4	71
80	Isolation and Characterization of Nontubular Sca-1+Linâ^' Multipotent Stem/Progenitor Cells from Adult Mouse Kidney. Journal of the American Society of Nephrology: JASN, 2006, 17, 3300-3314.	3.0	173
81	Tolerance induction by third-party "off-the-shelf―CD4+CD25+ Treg cells. Experimental Hematology, 2006, 34, 66-71.	0.2	45
82	Overcoming T cell–mediated rejection of bone marrow allografts by T-regulatory cells: Synergism with veto cells and rapamycin. Experimental Hematology, 2006, 34, 802-808.	0.2	28
83	Multiple Imprinted and Stemness Genes Provide a Link between Normal and Tumor Progenitor Cells of the Developing Human Kidney. Cancer Research, 2006, 66, 6040-6049.	0.4	127
84	Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19075-19080.	3.3	31
85	Progenitor Cell Therapy for Kidney Regeneration. , 2006, , 209-223.		0
86	The Trimera Mouse Model of HBV and HCV Infection. , 2005, 25, 146-160.		0
87	Immune regulatory activity of CD34+ progenitor cells: evidence for a deletion-based mechanism mediated by TNF-α. Blood, 2005, 105, 2585-2593.	0.6	60
88	Eradication of B-CLL by autologous and allogeneic host nonreactive anti–third-party CTLs. Blood, 2005, 105, 3365-3371.	0.6	16
89	ICOS: a new important player in BMT. Blood, 2005, 105, 3006-3007.	0.6	0
90	Embryonic pig liver, pancreas, and lung as a source for transplantation: Optimal organogenesis without teratoma depends on distinct time windows. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2928-2933.	3.3	56

Yair Y Reisner

#	Article	IF	CITATIONS
91	A novel small animal model for HIVâ€1 infection. FASEB Journal, 2005, 19, 1149-1151.	0.2	10
92	Hematopoietic Stem Cell Transplantation across Major Genetic Barriers: Tolerance Induction by Megadose CD34 Cells and Other Veto Cells. Annals of the New York Academy of Sciences, 2005, 1044, 70-83.	1.8	24
93	Large-Scale Preparation of Human Anti—Third-Party Veto Cytotoxic T Lymphocytes Depleted of Graft-Versus-Host Reactivity: A New Source for Graft Facilitating Cells in Bone Marrow Transplantation. Human Immunology, 2005, 66, 644-652.	1.2	10
94	Full Haplotype-Mismatched Hematopoietic Stem-Cell Transplantation: A Phase II Study in Patients With Acute Leukemia at High Risk of Relapse. Journal of Clinical Oncology, 2005, 23, 3447-3454.	0.8	677
95	The Role of ERK5 Signaling in Tolerance Induction by Veto CTLs Blood, 2005, 106, 3302-3302.	0.6	1
96	Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. I. Relative Reactivity of Different Veto Cells. Journal of Immunology, 2004, 173, 6654-6659.	0.4	20
97	Tolerance Induction by Veto CTLs in the TCR Transgenic 2C Mouse Model. II. Deletion of Effector Cells by Fas-Fas Ligand Apoptosis. Journal of Immunology, 2004, 173, 6660-6666.	0.4	37
98	Embryonic committed stem cells as a solution to kidney donor shortage. Expert Opinion on Biological Therapy, 2004, 4, 443-454.	1.4	17
99	Crossing the HLA barriers. Blood Cells, Molecules, and Diseases, 2004, 33, 206-210.	0.6	3
100	Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia. Blood Cells, Molecules, and Diseases, 2004, 33, 294-302.	0.6	17
101	Engraftment of human early kidney precursors. Transplant Immunology, 2004, 12, 241-247.	0.6	15
102	Effective Deletion of Anti-Donor Host Memory Effector Cells by Anti-3rd Party Veto CTLs: Implications to Tolerance Induction in Presensitized Bone Marrow Recipients Blood, 2004, 104, 44-44.	0.6	2
103	Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. Journal of Clinical Immunology, 2003, 23, 91-99.	2.0	15
104	Human and porcine early kidney precursors as a new source for transplantation. Nature Medicine, 2003, 9, 53-60.	15.2	267
105	Hematopoietic Stem Cell Transplantation across Major Genetic Barriers. Annals of the New York Academy of Sciences, 2003, 996, 72-79.	1.8	23
106	Anti–third-party veto CTLs overcome rejection of hematopoietic allografts: synergism with rapamycin and BM cell dose. Blood, 2003, 102, 1943-1950.	0.6	48
107	The Role of T Cell Depletion in Bone Marrow Transplantation. , 2003, , 327-342.		0
108	Human Colon Adenocarcinoma in the SCID/CB6 Radiation Chimera Is Susceptible to Adoptive Transfer of Allogeneic Human Peripheral Blood Mononuclear Cells. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 883-893.	1.8	3

#	Article	IF	CITATIONS
109	Megadose of hematopoietic stem cells for haploidentical transplants. Current Opinion in Organ Transplantation, 2002, 7, 294-298.	0.8	0
110	Tolerance induction by megadose hematopoietic progenitor cells: expansion of veto cells by short-term culture of purified human CD34+ cells. Blood, 2002, 99, 4174-4181.	0.6	93
111	Transplants across human leukocyte antigen barriers. Seminars in Hematology, 2002, 39, 48-56.	1.8	66
112	T cells from newborn humans are fully capable of developing into cytotoxic T lymphocyte effector cells in adoptive hosts. Transplantation, 2002, 73, 803-810.	0.5	3
113	Engraftment and Differentiation of Human Metanephroi into Functional Mature Nephrons after Transplantation into Mice Is Accompanied by a Profile of Gene Expression Similar to Normal Human Kidney Development. Journal of the American Society of Nephrology: JASN, 2002, 13, 977-990.	3.0	82
114	Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. European Journal of Immunology, 2001, 31, 2071-2079.	1.6	45
115	Stem Cell Transplantation across Major Genetic Barriers. Annals of the New York Academy of Sciences, 2001, 938, 322-327.	1.8	6
116	Reduced hepatitis B virus surface antigen-specific Th1 helper cell frequency of chronic HBV carriers is associated with a failure to produce antigen-specific antibodies in the Trimera mouse. Hepatology, 2000, 31, 480-487.	3.6	31
117	Tolerance induction by â€~megadose' transplants of CD34+ stem cells: a new option for leukemia patients without an HLA-matched donor. Current Opinion in Immunology, 2000, 12, 536-541.	2.4	71
118	Human Interleukin-6 Facilitates Hepatitis B Virus Infection in Vitro and in Vivo. Virology, 2000, 270, 299-309.	1.1	33
119	Preclinical Evaluation of Two Human Anti–Hepatitis B Virus(HBV) Monoclonal Antibodies in the HBV-Trimera Mouse Model and in HBV Chronic Carrier Chimpanzees. Hepatology, 2000, 32, 588-596.	3.6	82
120	IN VIVO MODULATION OF THE ALLOGENEIC IMMUNE RESPONSE BY HUMAN FETAL KIDNEYS. Transplantation, 2000, 69, 1470-1478.	0.5	50
121	Improved Outcome With T-Cell–Depleted Bone Marrow Transplantation for Acute Leukemia. Journal of Clinical Oncology, 1999, 17, 1545-1545.	0.8	92
122	Induction of Donor-Type Chimerism and Transplantation Tolerance Across Major Histocompatibility Barriers in Sublethally Irradiated Mice by Sca-1+Linâ^² Bone Marrow Progenitor Cells: Synergism With Non-Alloreactive (Host × Donor)F1 T Cells. Blood, 1999, 94, 3212-3221.	0.6	68
123	Acute cellular rejection of human renal tissue by adoptive transfer of allogeneic human peripheral blood mononuclear cells into chimeric rats: sequential gene expression of cytokines, chemokines and cytolytic effector molecules, and their regulation by CTLA-4–lg. International Immunology, 1999, 11, 1673-1683.	1.8	15
124	Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. International Immunology, 1999, 11, 1043-1051.	1.8	56
125	Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Trends in Immunology, 1999, 20, 343-347.	7.5	60
126	Antigenâ€specific B and T cells in human/mouse radiation chimera following immunizationin vivo. Immunology, 1999, 96, 634-641.	2.0	16

#	Article	IF	CITATIONS
127	The Role of Megadose CD34+ Progenitor Cells in the Treatment of Leukemia Patients without a Matched Donor and in Tolerance Induction for Organ Transplantation. Annals of the New York Academy of Sciences, 1999, 872, 336-350.	1.8	30
128	The hepatitis B virus-trimera mouse: A model for human HBV infection and evaluation of anti-HBV therapeutic agents. Hepatology, 1999, 29, 553-562.	3.6	97
129	T cell control of staphylococcal enterotoxin B (SEB) lethal sensitivity in mice: CD4+ CD45RBbright / CD4+ CD45RBdim balance defines susceptibility to SEB toxicity. European Journal of Immunology, 1999, 29, 1375-1382.	1.6	3
130	DONOR-TYPE CHIMERISM DETERMINATION BY COMPETITIVE POLYMERASE CHAIN REACTION (PCR) IN A PRIMATE MODEL FOR BONE MARROW TRANSPLANTATION1. Transplantation, 1999, 68, 1573-1577.	0.5	4
131	Induction of Donor-Type Chimerism and Transplantation Tolerance Across Major Histocompatibility Barriers in Sublethally Irradiated Mice by Sca-1+Linâ^ Bone Marrow Progenitor Cells: Synergism With Non-Alloreactive (Host × Donor)F1 T Cells. Blood, 1999, 94, 3212-3221.	0.6	3
132	The Trimera mouse: generating human monoclonal antibodies and an animal model for human diseases. Trends in Biotechnology, 1998, 16, 242-246.	4.9	41
133	Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies. Immunology, 1998, 94, 410-416.	2.0	8
134	Chimerism, Hematopoietic. , 1998, , 544-549.		0
135	Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA Haplotype. New England Journal of Medicine, 1998, 339, 1186-1193.	13.9	1,141
136	TOLERANCE INDUCTION BY "MEGADOSE" HEMATOPOIETIC TRANSPLANTS. Transplantation, 1998, 65, 1386-1393.	0.5	172
137	Use of stem cells from mismatched related donors. Current Opinion in Hematology, 1997, 4, 419-422.	1.2	24
138	A Model for Human B-Chronic Lymphocytic Leukemia in Human/Mouse Radiation Chimera: Evidence for Tumor-Mediated Suppression of Antibody Production in Low-Stage Disease. Blood, 1997, 89, 2210-2218.	0.6	35
139	ENGRAFTED HUMAN T AND B LYMPHOCYTES FORM MIXED FOLLICLES IN LYMPHOID ORGANS OF HUMAN/MOUSE AND HUMAN/RAT RADIATION CHIMERA1. Transplantation, 1997, 63, 1166-1171.	0.5	17
140	ENGRAFTMENT OF HUMAN KIDNEY TISSUE IN RAT RADIATION CHIMERA. Transplantation, 1997, 64, 1541-1550.	0.5	31
141	ENGRAFTMENT OF HUMAN KIDNEY TISSUE IN RAT RADIATION CHIMERA. Transplantation, 1997, 64, 1550-1558.	0.5	71
142	Human → mouse radiation chimera do not develop Epstein-Barr virus lymphoma. Immunology Letters, 1996, 49, 155-161.	1.1	12
143	ALLOGRAFT AND XENOGRAFT REJECTION IN C3H/SCID MICE. Transplantation, 1996, 61, 777-783.	0.5	8
144	CONVERSION OF NORMAL RATS INTO SCID-LIKE ANIMALS BY MEANS OF BONE MARROW TRANSPLANTATION FROM SCID DONORS ALLOWS ENGRAFTMENT OF HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS. Transplantation, 1995, 60, 740-747.	0.5	16

#	Article	IF	CITATIONS
145	Natural antibodies do not inhibit xenogeneic transplantation of human PBL in lethally irradiated mice. Xenotransplantation, 1995, 2, 8-18.	1.6	0
146	Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Medicine, 1995, 1, 1268-1273.	15.2	325
147	Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Trends in Immunology, 1995, 16, 437-440.	7.5	171
148	Hematopoietic stem cell transplantation for cancer therapy. Current Opinion in Immunology, 1995, 7, 687-693.	2.4	12
149	Lethally irradiated normal strains of mice radioprotected with SCID bone marrow develop sensitivity to low doses of staphylococcal enterotoxin B. Immunology Letters, 1995, 46, 9-14.	1.1	8
150	INDUCTION OF PROLONGED TOLERANCE TO THIRD-PARTY SKIN GRAFTS FOLLOWING FULLY ALLOGENEIC BONE MARROW TRANSPLANTATION IN MICE. Transplantation, 1993, 55, 633-638.	0.5	4
151	Purification in large amounts of \hat{l}^2 -d-galactoside-binding lectins from a murine thymic epithelial cell line. Carbohydrate Research, 1991, 213, 345-352.	1.1	1
152	Engraftment of T-cell-depleted bone marrow in murine models for allogeneic bone marrow transplantation. Cancer Treatment and Research, 1990, 50, 9-25.	0.2	5
153	Bone Marrow Transplantation after the Chernobyl Nuclear Accident. New England Journal of Medicine, 1989, 321, 205-212.	13.9	141
154	THE ROLE OF BONE-MARROW TRANSPLANTS AFTER NUCLEAR ACCIDENTS. Lancet, The, 1988, 331, 923-926.	6.3	15
155	GRAFT REJECTION AND GRAFT-VERSUS-HOST DISEASE: MIRROR IMAGES. Lancet, The, 1986, 327, 1468-1470.	6.3	112
156	Changes in sialyltransferase activity during murine T cell differentiation. Cellular Immunology, 1986, 100, 10-19.	1.4	18
157	[171 Fractionation of subpopulations of mouse and human lymphocytes by peanut agglutinin or soybean agglutinin. Methods in Enzymology, 1984, 108, 168-179.	0.4	24
158	Bone marrow transplantation—An expanding approach to treatment of many diseases. Cellular Immunology, 1983, 82, 36-54.	1.4	38
159	Binding of peanut agglutinin to normal human lymphocytes and to leukemic cells. Leukemia Research, 1982, 6, 123-125.	0.4	5
160	ALLOGENEIC BONE MARROW TRANSPLANTATION USING STEM CELLS FRACTIONATED BY LECTINS: VI, IN VITRO ANALYSIS OF HUMAN AND MONKEY BONE MARROW CELLS FRACTIONATED BY SHEEP RED BLOOD CELLS AND SOYBEAN AGGLUTININ. Lancet, The, 1980, 316, 1320-1324.	6.3	103
161	Cell fractionation by lectins. Trends in Biochemical Sciences, 1980, 5, 29-31.	3.7	29
162	Studies on the Interaction of Lectins with Saccharides on Lymphocyte Cell Surfaces. ACS Symposium Series, 1979, , 1-11.	0.5	3

#	Article	IF	CITATIONS
163	Selective expression of murine lymphocyte alloantigens controlled by the X-chromosome. Immunogenetics, 1979, 9, 119-124.	1.2	10
164	Characterization of embryonic liver suppressor cells by peanut agglutinin. Cellular Immunology, 1979, 47, 347-355.	1.4	30
165	Inhibition or acceleration of tumor growth by subpopulations of thymus cells separable by a peanut lectin. Cellular Immunology, 1978, 37, 134-141.	1.4	25
166	T-cell neoplasm induced by subcutaneous transplantation of a plasmacytoma: Characterization of tumor cells. Cellular Immunology, 1977, 34, 180-186.	1.4	3
167	Interaction of peanut agglutinin, a lectin specific for nonreducing terminal d-galactosyl residues, with embryonal carcinoma cells. Developmental Biology, 1977, 61, 20-27.	0.9	120
168	Use of soybean agglutinin for the separation of mouse B and T lymphocytes. Biochemical and Biophysical Research Communications, 1976, 72, 1585-1591.	1.0	126
169	Separation of mouse thymocytes into two subpopulations by the use of peanut agglutinin. Cellular Immunology, 1976, 25, 129-134.	1.4	513
170	Applying Human Cells to Organogenesis and Transplantation. , 0, , 353-373.		3

11